SG Americas Securities LLC Boosts Stake in West Pharmaceutical Services, Inc. $WST

SG Americas Securities LLC increased its holdings in shares of West Pharmaceutical Services, Inc. (NYSE:WST) by 278.4% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 100,909 shares of the medical instruments supplier’s stock after acquiring an additional 74,245 shares during the quarter. SG Americas Securities LLC owned about 0.14% of West Pharmaceutical Services worth $27,764,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. Vanguard Group Inc. raised its holdings in West Pharmaceutical Services by 4.2% in the 3rd quarter. Vanguard Group Inc. now owns 9,704,948 shares of the medical instruments supplier’s stock valued at $2,545,899,000 after acquiring an additional 388,144 shares during the last quarter. State Street Corp boosted its holdings in shares of West Pharmaceutical Services by 2.1% during the 2nd quarter. State Street Corp now owns 3,271,866 shares of the medical instruments supplier’s stock worth $715,884,000 after purchasing an additional 68,330 shares during the last quarter. Artisan Partners Limited Partnership grew its position in shares of West Pharmaceutical Services by 22.2% in the third quarter. Artisan Partners Limited Partnership now owns 2,770,920 shares of the medical instruments supplier’s stock valued at $726,895,000 after purchasing an additional 503,601 shares in the last quarter. Durable Capital Partners LP increased its holdings in shares of West Pharmaceutical Services by 12.7% in the third quarter. Durable Capital Partners LP now owns 1,172,583 shares of the medical instruments supplier’s stock valued at $307,604,000 after purchasing an additional 131,935 shares during the last quarter. Finally, Invesco Ltd. increased its holdings in shares of West Pharmaceutical Services by 1.1% in the second quarter. Invesco Ltd. now owns 959,525 shares of the medical instruments supplier’s stock valued at $209,944,000 after purchasing an additional 10,070 shares during the last quarter. Hedge funds and other institutional investors own 93.90% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on WST. Zacks Research raised West Pharmaceutical Services from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, January 21st. UBS Group reaffirmed a “buy” rating and issued a $340.00 target price on shares of West Pharmaceutical Services in a research note on Friday, February 13th. Barclays reduced their price target on West Pharmaceutical Services from $325.00 to $265.00 and set an “equal weight” rating on the stock in a report on Friday, February 13th. Evercore dropped their price objective on shares of West Pharmaceutical Services from $390.00 to $320.00 and set an “outperform” rating for the company in a report on Tuesday, February 3rd. Finally, Morgan Stanley started coverage on shares of West Pharmaceutical Services in a research report on Monday, December 1st. They set an “equal weight” rating and a $285.00 price objective for the company. Three investment analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat.com, West Pharmaceutical Services presently has an average rating of “Buy” and a consensus target price of $314.56.

West Pharmaceutical Services Price Performance

WST stock opened at $248.12 on Friday. The business has a fifty day moving average of $243.70 and a two-hundred day moving average of $261.44. The company has a quick ratio of 2.34, a current ratio of 3.02 and a debt-to-equity ratio of 0.06. The stock has a market cap of $17.88 billion, a price-to-earnings ratio of 36.54, a price-to-earnings-growth ratio of 2.63 and a beta of 1.17. West Pharmaceutical Services, Inc. has a 52-week low of $187.43 and a 52-week high of $322.34.

West Pharmaceutical Services (NYSE:WST) last announced its quarterly earnings results on Thursday, February 12th. The medical instruments supplier reported $2.04 EPS for the quarter, beating the consensus estimate of $1.83 by $0.21. The business had revenue of $805.00 million for the quarter, compared to analyst estimates of $795.70 million. West Pharmaceutical Services had a return on equity of 17.90% and a net margin of 16.06%.The company’s quarterly revenue was up 7.5% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.82 EPS. West Pharmaceutical Services has set its FY 2026 guidance at 7.850-8.200 EPS. As a group, research analysts anticipate that West Pharmaceutical Services, Inc. will post 6.62 earnings per share for the current year.

West Pharmaceutical Services announced that its Board of Directors has authorized a share repurchase plan on Tuesday, February 17th that authorizes the company to buyback $1.00 billion in shares. This buyback authorization authorizes the medical instruments supplier to repurchase up to 5.6% of its stock through open market purchases. Stock buyback plans are typically an indication that the company’s board of directors believes its shares are undervalued.

West Pharmaceutical Services Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, May 6th. Shareholders of record on Wednesday, April 29th will be given a $0.22 dividend. The ex-dividend date of this dividend is Wednesday, April 29th. This represents a $0.88 dividend on an annualized basis and a yield of 0.4%. West Pharmaceutical Services’s dividend payout ratio is presently 12.96%.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.